European Medicines Agency enhances cooperation with EU drug-monitoring agency on psychoactive and abused medicines.
Today, 17 September 2012, the exchange of information on new psychoactive substances and abused medicines has been enhanced today with an amended working arrangement between the European Medicines Agency (EMA) and the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). This update reflects the new pharmacovigilance legislation, which states that the EMA and the EMCDDA ‘shall exchange information that they receive on the abuse of medicinal products including information related to illicit drugs’. The EMA will now inform the EMCDDA of any validated signals of suspected side effects of medicines that are related to drug abuse. Other features of today’s arrangement include the possibility for the EMA to consult the EMCDDA when defining risk management plans for selected medicines.